Luye Pharma Group (HK:2186) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Luye Pharma Group has announced the inclusion of several innovative drugs, including Ruoxinlin and Baituowei, in China’s 2024 National Reimbursement Drug List. This development is expected to enhance patient access and accelerate commercialization, potentially boosting financial returns for the company. The inclusion marks a significant milestone for Luye’s proprietary antidepressant, Ruoxinlin, as a breakthrough ‘Made-in-China’ drug.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue